Rankings
▼
Calendar
TSHA Q1 2022 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena
TSHA
Taysha Gene Therapies, Inc.
$1B
Q1 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$50M
Net Income
-$50M
EPS (Diluted)
$-1.32
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$41M
Free Cash Flow
-$52M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$166M
Total Liabilities
$115M
Stockholders' Equity
$51M
Cash & Equivalents
$97M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$50M
-$32M
-54.7%
Net Income
-$50M
-$32M
-57.1%
← FY 2022
All Quarters
Q2 2022 →